Navigation Links
Vanderbilt study looks at benefits of progestogens to prevent early childbirth
Date:9/10/2012

Pregnant women who have had prior preterm births may avoid a subsequent early birth if given progestogens, which are natural or synthetic forms of progesterone, a female hormone that naturally increases during pregnancy, a Vanderbilt analysis shows.

Women who have had prior preterm births and are given progestogens while expecting a single child show some benefit from additional hormone, Vanderbilt researchers reported in a systematic review released on Thursday in Obstetrics & Gynecology, the official publication of the American College of Obstetricians and Gynecologists, commonly referred to as The Green Journal.

The researchers looked at 34 prior studies of women who were given progestogens for prior preterm births, multiple gestations, preterm labor, short cervix or other indications. Each study included 20 or more women who were given the medication by injection, orally or vaginally, and took place between January 1966 and October 2011.

The work was funded by the Agency for Healthcare Research and Quality (AHRQ).

In contrast, the researchers found progestogens don't seem to help prevent preterm labor in women carrying twins or triplets. And evidence supporting giving progestogens for all other uses is insufficient to guide clinical care.

The review provides valuable information, but more study is needed, said Frances E. Likis, DrPH, N.P., CNM, research assistant professor of Medicine and the lead author of the review. "While we know that women have progesterone levels that go up in early pregnancy and remain elevated, we still don't understand why giving extra progestogens would help them stay pregnant," she said. "The pharmaceutical effects are not well understood."

The United States has a very high preterm birth rate and was among the top 10 countries with the highest numbers of preterm births in 2010. "We haven't been able to move that number very well, and although it's gone down somewhat in past years, it's not a dramatic drop," she said.

Along with the systematic review, the AHRQ is releasing Vanderbilt's longer report on progestogens for preterm birth prevention online today. The full report looks at other questions such as whether how progestogens are administered makes a difference in effectiveness and the adverse effects of progestogens for preterm birth.

Progestogens are usually given by clinicians to women at the beginning of the second trimester through 37 weeks gestation or until the baby is born. Most women receive the medication once a week by injection, although some receive it vaginally. Very few take an oral dose.

Likis said asking generally whether progestogens are beneficial isn't possible. "Women are being given progestogens for very different reasons, so in our review, we decided to look at effectiveness by why women took it. Having had a previous preterm birth is different from having twins, and that's how clinicians make decisions. They don't just look at women and say 'you're at risk,' they say 'what is your risk factor?'"

To look at complications, a larger group of women is needed, she said. "There's relatively little evidence about whether babies had complications, and there's also very little information about long-term health effects in the infant," she said. "There's a lot more that needs to be studied. There's a lot of work to be done."
'/>"/>

Contact: Craig Boerner
craig.boerner@vanderbilt.edu
615-322-4747
Vanderbilt University Medical Center
Source:Eurekalert

Related medicine news :

1. Vanderbilt-led study reveals racial disparities in prostate cancer care
2. Vanderbilt researchers find proteins may point way to new prostate cancer drug targets
3. Vanderbilt study finds obesity linked to kidney injury after heart surgery
4. Young Children Treated for Cancer May Be at Risk for PTSD: Study
5. Physicians empathy directly associated with positive clinical outcomes, confirms large study
6. Study identifies genes associated with genomic expansions that cause disease
7. Multiple Methods Can Safely Help Babies Get to Sleep, Study Shows
8. Large lung cancer study shows potential for more targeted therapies
9. Chemo Brain After Breast Cancer Backed by Study
10. X-Rays May Up Breast Cancer Risk for Women With Certain Genes: Study
11. Cedars-Sinai Heart Institute awarded $1.3 million to study cardiac stem cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... NEW ORLEANS, La. (PRWEB) , ... July 21, ... ... tool to allow 4th-year medical students improve their chances of acceptance to a ... particularly for those who have earned degrees outside the U.S. , According to ...
(Date:7/21/2017)... ... July 21, 2017 , ... Sharon Kleyne is proud of ... her research center at Bio-Logic Aqua Research® Water Life Science®, has been released ... of sufferers of blindness. “We think that Nature’s Tears® EyeMist® will contribute to ...
(Date:7/21/2017)... TORONTO, ONTARIO, CANADA (PRWEB) , ... July 21, ... ... with over 80% follow-up at 10 years, researchers from the Multicenter Orthopaedics Outcome ... knee-related quality of life a decade after surgery, though activity levels decline over ...
(Date:7/21/2017)... CANADA (PRWEB) , ... July 21, 2017 , ... ... insight into why concussion rates are on the rise, say researchers presenting their ... today in Toronto, Ontario, Canada. , “The combination of evaluating the patterns of ...
(Date:7/20/2017)... ... July 20, 2017 , ... ChenMed , a ... joined JenCare Senior Medical Center as Richmond Chief Medical Officer. Dr. ... Medicine, and Associate Chief Medical Officer of Ambulatory Services for the UVA Health System, ...
Breaking Medicine News(10 mins):
(Date:7/5/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) ... company focused on the development of oral drug delivery systems, ... Securities Authority to dual-list its common stock on the Tel ... on the TASE on July 12, 2017 under the ticker ... it is expected that Oramed will be included in the ...
(Date:7/5/2017)... , July 5, 2017   BioLife Solutions ... developer, manufacturer and marketer of proprietary clinical grade cell ... freeze media ("BioLife"), today announced that it has ... debt holder and largest shareholder, to modify its existing ... Pursuant to the modification, WAVI agreed to exchange its ...
(Date:6/30/2017)... ROCKVILLE, Md. , June 30, 2017 ... that since the start of May, at least ten ... financings include private investments, public offerings and a loan ... $3.3 million to almost $80 million.  Kalorama Information provides ... customers of its Diagnostics Knowledge Center. ...
Breaking Medicine Technology: